Endometrial Cancer. Guideline of the DGGG, DKG and DKH (S3-Level, AWMF Registry Number 032/034-OL, September 2022). Part 1 with Recommendations on the Epidemiology, Screening, Diagnosis and Hereditary Factors of Endometrial Cancer, Geriatric Assessment and Supply Structures

 

 Permissions and Reprints

Abstract

Summary The S3-guideline on endometrial cancer, first published in April 2018, was reviewed in its entirety between April 2020 and January 2022 and updated. The review was carried out at the request of German Cancer Aid as part of the Oncology Guidelines Program and the lead coordinators were the German Society for Gynecology and Obstetrics (DGGG), the Gynecology Oncology Working Group (AGO) of the German Cancer Society (DKG) and the German Cancer Aid (DKH). The guideline update was based on a systematic search and assessment of the literature published between 2016 and 2020. All statements, recommendations and background texts were reviewed and either confirmed or amended. New statements and recommendations were included where necessary.

Aim The use of evidence-based risk-adapted therapies to treat women with endometrial cancer of low risk prevents unnecessarily radical surgery and avoids non-beneficial adjuvant radiation therapy and/or chemotherapy. For women with endometrial cancer and a high risk of recurrence, the guideline defines the optimum level of radical surgery and indicates whether chemotherapy and/or adjuvant radiation therapy is necessary. This should improve the survival rates and quality of life of these patients. The S3-guideline on endometrial cancer and the quality indicators based on the guideline aim to provide the basis for the work of certified gynecological cancer centers.

Methods The guideline was first compiled in 2018 in accordance with the requirements for S3-level guidelines and was updated in 2022. The update included an adaptation of the source guidelines identified using the German Instrument for Methodological Guideline Appraisal (DELBI). The update also used evidence reviews which were created based on selected literature obtained from systematic searches in selected literature databases using the PICO process. The Clinical Guidelines Service Group was tasked with carrying out a systematic search and assessment of the literature. Their results were used by interdisciplinary working groups as a basis for developing suggestions for recommendations and statements which were then modified during structured online consensus conferences and/or additionally amended online using the DELPHI process to achieve a consensus.

Recommendations Part 1 of this short version of the guideline provides recommendations on epidemiology, screening, diagnosis, and hereditary factors. The epidemiology of endometrial cancer and the risk factors for developing endometrial cancer are presented. The options for screening and the methods used to diagnose endometrial cancer are outlined. Recommendations are given for the prevention, diagnosis, and therapy of hereditary forms of endometrial cancer. The use of geriatric assessment is considered and existing structures of care are presented.

Publication History

Received: 17 March 2023

Accepted after revision: 22 June 2023

Article published online:
15 August 2023

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

• References/Literatur

• 1 Robert Koch-Institut, Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V.. Krebs in Deutschland 2015/2016. 2019. Accessed July 25, 2023 at: https://www.krebsdaten.de/Krebs/DE/Content/Publikationen/Krebs in Deutschland/kid2019krebs_in_deutschland_2019.pdf?_blob=publicationFile
  PubMedGoogle Scholar
• 2 Tempfer CB, Hilal Z, Kern P. et al. Menopausal Hormone Therapy and Risk of Endometrial Cancer: A Systematic Review. Cancers (Basel) 2020; 12: 2195
  CrossrefPubMedGoogle Scholar
• 3 Lacey jr. JV, Brinton LA, Lubin JH. et al. Endometrial carcinoma risks among menopausal estrogen plus progestin and unopposed estrogen users in a cohort of postmenopausal women. Cancer Epidemiol Biomarkers Prev 2005; 14: 1724-1731
  CrossrefPubMedGoogle Scholar
• 4 Allen NE, Tsilidis KK, Key TJ. et al. Menopausal hormone therapy and risk of endometrial carcinoma among postmenopausal women in the European Prospective Investigation Into Cancer and Nutrition. Am J Epidemiol 2010; 172: 1394-1403
  CrossrefPubMedGoogle Scholar
• 5 Marjoribanks J, Farquhar C, Roberts H. et al. Long-term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev 2017; (01) CD004143
  PubMedGoogle Scholar
• 6 Beral V, Bull D, Reeves G. Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet 2005; 365: 1543-1551
  CrossrefPubMedGoogle Scholar
• 7 Nelson HD, Humphrey LL, Nygren P. et al. Postmenopausal hormone replacement therapy: scientific review. JAMA 2002; 288: 872-881
  CrossrefPubMedGoogle Scholar
• 8 Grady D, Gebretsadik T, Kerlikowske K. et al. Hormone replacement therapy and endometrial cancer risk: a meta-analysis (Structured abstract). Obstet Gynecol 1995; 85: 304-313
  CrossrefPubMedGoogle Scholar
• 9 Razavi P, Pike MC, Horn-Ross PL. et al. Long-term postmenopausal hormone therapy and endometrial cancer. Cancer Epidemiol Biomarkers Prev 2010; 19: 475-483
  CrossrefPubMedGoogle Scholar
• 10 Chlebowski RT, Anderson GL, Sarto GE. et al. Continuous Combined Estrogen Plus Progestin and Endometrial Cancer: The Womenʼs Health Initiative Randomized Trial. J Natl Cancer Inst 2015; 108: djv350
  CrossrefPubMedGoogle Scholar
• 11 Mørch LS, Kjaer SK, Keiding N. et al. The influence of hormone therapies on type I and II endometrial cancer: A nationwide cohort study. Int J Cancer 2016; 138: 1506-1515
  CrossrefPubMedGoogle Scholar
• 12 Fournier A, Dossus L, Mesrine S. et al. Risks of endometrial cancer associated with different hormone replacement therapies in the E3 N cohort, 1992–2008. Am J Epidemiol 2014; 180: 508-517
  CrossrefPubMedGoogle Scholar
• 13 Doherty JA, Cushing-Haugen KL, Saltzman BS. et al. Long-term use of postmenopausal estrogen and progestin hormone therapies and the risk of endometrial cancer. Am J Obstet Gynecol 2007; 197: 139.e1-139.e7
  CrossrefPubMedGoogle Scholar
• 14 Sjögren LL, Mørch LS, Løkkegaard E. Hormone replacement therapy and the risk of endometrial cancer: A systematic review. Maturitas 2016; 91: 25-35
  CrossrefPubMedGoogle Scholar
• 15 Emons G, Mustea A, Tempfer C. Tamoxifen and Endometrial Cancer: A Janus-Headed Drug. Cancers (Basel) 2020; 12: 2535
  CrossrefPubMedGoogle Scholar
• 16 Nelson HD, Smith ME, Griffin JC. et al. Use of medications to reduce risk for primary breast cancer: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2013; 158: 604-614
  CrossrefPubMedGoogle Scholar
• 17 Braithwaite RS, Chlebowski RT, Lau J. et al. Meta-analysis of vascular and neoplastic events associated with tamoxifen. J Gen Intern Med 2003; 18: 937-947
  CrossrefPubMedGoogle Scholar
• 18 Al-Mubarak M, Tibau A, Templeton AJ. et al. Extended adjuvant tamoxifen for early breast cancer: a meta-analysis. PLoS One 2014; 9: e88238
  CrossrefPubMedGoogle Scholar
• 19 DeMichele A, Troxel AB, Berlin JA. et al. Impact of raloxifene or tamoxifen use on endometrial cancer risk: a population-based case-control study. J Clin Oncol 2008; 26: 4151-4159
  CrossrefPubMedGoogle Scholar
• 20 Ignatov A, Ortmann O. Endocrine Risk Factors of Endometrial Cancer: Polycystic Ovary Syndrome, Oral Contraceptives, Infertility, Tamoxifen. Cancers (Basel) 2020; 12: 1766
  CrossrefPubMedGoogle Scholar
• 21 Collaborative Group on Epidemiological Studies on Endometrial Cancer. Endometrial cancer and oral contraceptives: an individual participant meta-analysis of 27 276 women with endometrial cancer from 36 epidemiological studies. Lancet Oncol 2015; 16: 1061-1070
  CrossrefPubMedGoogle Scholar
• 22 Gierisch JM, Coeytaux RR, Urrutia RP. et al. Oral contraceptive use and risk of breast, cervical, colorectal, and endometrial cancers: a systematic review. Cancer Epidemiol Biomarkers Prev 2013; 22: 1931-1943
  CrossrefPubMedGoogle Scholar
• 23 Parazzini F, Pelucchi C, Talamini R. et al. Use of fertility drugs and risk of endometrial cancer in an Italian case-control study. Eur J Cancer Prev 2010; 19: 428-430
  CrossrefPubMedGoogle Scholar
• 24 Siristatidis C, Sergentanis TN, Kanavidis P. et al. Controlled ovarian hyperstimulation for IVF: impact on ovarian, endometrial and cervical cancer–a systematic review and meta-analysis. Hum Reprod Update 2013; 19: 105-123
  CrossrefPubMedGoogle Scholar
• 25 Skalkidou A, Sergentanis TN, Gialamas SP. et al. Risk of endometrial cancer in women treated with ovary-stimulating drugs for subfertility. Cochrane Database Syst Rev 2017; (03) CD010931
  PubMedGoogle Scholar
• 26 Ettinger B, Kenemans P, Johnson SR. et al. Endometrial effects of tibolone in elderly, osteoporotic women. Obstet Gynecol 2008; 112: 653-659
  CrossrefPubMedGoogle Scholar
• 27 Dossus L, Allen N, Kaaks R. et al. Reproductive risk factors and endometrial cancer: the European Prospective Investigation into Cancer and Nutrition. Int J Cancer 2009; 127: 442-451
  CrossrefPubMedGoogle Scholar
• 28 Setiawan VW, Pike MC, Karageorgi S. et al. Age at last birth in relation to risk of endometrial cancer: pooled analysis in the epidemiology of endometrial cancer consortium. Am J Epidemiol 2012; 176: 269-278
  CrossrefPubMedGoogle Scholar
• 29 Karageorgi S, Hankinson SE, Kraft P. et al. Reproductive factors and postmenopausal hormone use in relation to endometrial cancer risk in the Nursesʼ Health Study cohort 1976–2004. Int J Cancer 2009; 126: 208-216
  CrossrefPubMedGoogle Scholar
• 30 Friberg E, Orsini N, Mantzoros CS. et al. Diabetes mellitus and risk of endometrial cancer: a meta-analysis. Diabetologia 2007; 50: 1365-1374
  CrossrefPubMedGoogle Scholar
• 31 Barone BB, Yeh HC, Snyder CF. et al. Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. JAMA 2008; 300: 2754-2764
  CrossrefPubMedGoogle Scholar
• 32 Huang Y, Cai X, Qiu M. et al. Prediabetes and the risk of cancer: a meta-analysis. Diabetologia 2014; 57: 2261-2269
  CrossrefPubMedGoogle Scholar
• 33 Zhang ZH, Su PY, Hao JH. et al. The role of preexisting diabetes mellitus on incidence and mortality of endometrial cancer: a meta-analysis of prospective cohort studies. Int J Gynecol Cancer 2013; 23: 294-303
  CrossrefPubMedGoogle Scholar
• 34 Liao C, Zhang D, Mungo C. et al. Is diabetes mellitus associated with increased incidence and disease-specific mortality in endometrial cancer? A systematic review and meta-analysis of cohort studies. Gynecol Oncol 2014; 135: 163-171
  CrossrefPubMedGoogle Scholar
• 35 Luo J, Beresford S, Chen C. et al. Association between diabetes, diabetes treatment and risk of developing endometrial cancer. Br J Cancer 2014; 111: 1432-1439
  CrossrefPubMedGoogle Scholar
• 36 Gnagnarella P, Gandini S, La Vecchia C. et al. Glycemic index, glycemic load, and cancer risk: a meta-analysis. Am J Clin Nutr 2008; 87: 1793-1801
  CrossrefPubMedGoogle Scholar
• 37 Mulholland HG, Murray LJ, Cardwell CR. et al. Dietary glycaemic index, glycaemic load and endometrial and ovarian cancer risk: a systematic review and meta-analysis. Br J Cancer 2008; 99: 434-441
  CrossrefPubMedGoogle Scholar
• 38 Choi Y, Giovannucci E, Lee JE. Glycaemic index and glycaemic load in relation to risk of diabetes-related cancers: a meta-analysis. Br J Nutr 2012; 108: 1934-1947
  CrossrefPubMedGoogle Scholar
• 39 Nagle CM, Olsen CM, Ibiebele TI. et al. Glycemic index, glycemic load and endometrial cancer risk: results from the Australian National Endometrial Cancer study and an updated systematic review and meta-analysis. Eur J Nutr 2012; 52: 705-715
  CrossrefPubMedGoogle Scholar
• 40 Fearnley EJ, Marquart L, Spurdle AB. et al. Polycystic ovary syndrome increases the risk of endometrial cancer in women aged less than 50 years: an Australian case-control study. Cancer Causes Control 2010; 21: 2303-2308
  CrossrefPubMedGoogle Scholar
• 41 Gottschau M, Kjaer SK, Jensen A. et al. Risk of cancer among women with polycystic ovary syndrome: a Danish cohort study. Gynecol Oncol 2014; 136: 99-103
  CrossrefPubMedGoogle Scholar
• 42 Chittenden BG, Fullerton G, Maheshwari A. et al. Polycystic ovary syndrome and the risk of gynaecological cancer: a systematic review. Reprod Biomed Online 2009; 19: 398-405
  CrossrefPubMedGoogle Scholar
• 43 Haoula Z, Salman M, Atiomo W. Evaluating the association between endometrial cancer and polycystic ovary syndrome. Hum Reprod 2012; 27: 1327-1331
  CrossrefPubMedGoogle Scholar
• 44 Barry JA, Azizia MM, Hardiman PJ. Risk of endometrial, ovarian and breast cancer in women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update 2014; 20: 748-758
  CrossrefPubMedGoogle Scholar
• 45 Crosbie EJ, Zwahlen M, Kitchener HC. et al. Body mass index, hormone replacement therapy, and endometrial cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2010; 19: 3119-3130
  PubMedGoogle Scholar
• 46 Ward KK, Roncancio AM, Shah NR. et al. The risk of uterine malignancy is linearly associated with body mass index in a cohort of US women. Am J Obstet Gynecol 2013; 209: 579.e1-579.e5
  CrossrefPubMedGoogle Scholar
• 47 Renehan AG, Tyson M, Egger M. et al. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 2008; 371: 569-578
  CrossrefPubMedGoogle Scholar
• 48 Dobbins M, Decorby K, Choi BC. The Association between Obesity and Cancer Risk: A Meta-Analysis of Observational Studies from 1985 to 2011. ISRN Prev Med 2013; 2013: 680536
  CrossrefPubMedGoogle Scholar
• 49 Bergstrom A, Pisani P, Tenet V. et al. Overweight as an avoidable cause of cancer in Europe. Int J Cancer 2001; 91: 421-430
  CrossrefPubMedGoogle Scholar
• 50 Reeves KW, Carter GC, Rodabough RJ. et al. Obesity in relation to endometrial cancer risk and disease characteristics in the Womenʼs Health Initiative. Gynecol Oncol 2011; 121: 376-382
  CrossrefPubMedGoogle Scholar
• 51 Dörk T, Hillemanns P, Tempfer C. et al. Genetic Susceptibility to Endometrial Cancer: Risk Factors and Clinical Management. Cancers (Basel) 2020; 12: 2407
  CrossrefPubMedGoogle Scholar
• 52 Ma X, Zhao LG, Sun JW. et al. Association between breastfeeding and risk of endometrial cancer: a meta-analysis of epidemiological studies. Eur J Cancer Prev 2018; 27: 144-151
  CrossrefPubMedGoogle Scholar
• 53 Crosbie EJ, Zwahlen M, Kitchener HC. et al. Body mass index, hormone replacement therapy, and endometrial cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2010; 19: 3119-3130
  CrossrefPubMedGoogle Scholar
• 54 Kohler LN, Garcia DO, Harris RB. et al. Adherence to Diet and Physical Activity Cancer Prevention Guidelines and Cancer Outcomes: A Systematic Review. Cancer Epidemiol Biomarkers Prev 2016; 25: 1018-1028
  CrossrefPubMedGoogle Scholar
• 55 Zhang X, Rhoades J, Caan BJ. et al. Intentional weight loss, weight cycling, and endometrial cancer risk: a systematic review and meta-analysis. Int J Gynecol Cancer 2019; 29: 1361-1371
  CrossrefPubMedGoogle Scholar
• 56 Keum N, Ju W, Lee DH. et al. Leisure-time physical activity and endometrial cancer risk: dose-response meta-analysis of epidemiological studies. Int J Cancer 2014; 135: 682-694
  CrossrefPubMedGoogle Scholar
• 57 Gierach GL, Chang SC, Brinton LA. et al. Physical activity, sedentary behavior, and endometrial cancer risk in the NIH-AARP Diet and Health Study. Int J Cancer 2009; 124: 2139-2147
  CrossrefPubMedGoogle Scholar
• 58 Moore SC, Gierach GL, Schatzkin A. et al. Physical activity, sedentary behaviours, and the prevention of endometrial cancer. Br J Cancer 2010; 103: 933-938
  CrossrefPubMedGoogle Scholar
• 59 Voskuil DW, Monninkhof EM, Elias SG. et al. Physical activity and endometrial cancer risk, a systematic review of current evidence. Cancer Epidemiol Biomarkers Prev 2007; 16: 639-648
  CrossrefPubMedGoogle Scholar
• 60 Schmid D, Leitzmann MF. Television viewing and time spent sedentary in relation to cancer risk: a meta-analysis. J Natl Cancer Inst 2014; 106: dju098
  CrossrefPubMedGoogle Scholar
• 61 Soini T, Hurskainen R, Grenman S. et al. Cancer risk in women using the levonorgestrel-releasing intrauterine system in Finland. Obstet Gynecol 2014; 124: 292-299
  CrossrefPubMedGoogle Scholar
• 62 Felix AS, Gaudet MM, La Vecchia C. et al. Intrauterine devices and endometrial cancer risk: a pooled analysis of the Epidemiology of Endometrial Cancer Consortium. Int J Cancer 2014; 136: E410-E422
  CrossrefPubMedGoogle Scholar
• 63 Manchanda R, Saridogan E, Abdelraheim A. et al. Annual outpatient hysteroscopy and endometrial sampling (OHES) in HNPCC/Lynch syndrome (LS). Arch Gynecol Obstet 2012; 286: 1555-1562
  CrossrefPubMedGoogle Scholar
• 64 Helder-Woolderink JM, De Bock GH, Sijmons RH. et al. The additional value of endometrial sampling in the early detection of endometrial cancer in women with Lynch syndrome. Gynecol Oncol 2013; 131: 304-308
  CrossrefPubMedGoogle Scholar
• 65 Raatz H, Glinz D. Systematische Reviews und Bewertung der Qualität der Evidenz im Rahmen der S3-Leitlinie Endometriumkarzinom. 2015. Accessed June 14, 2023 at: https://www.leitlinienprogramm-onkologie.de/fileadmin/user_upload/Downloads/Leitlinien/Endometriumkarzinom/Evidenzbericht_Screening_CEB_Basel.pdf
  PubMedGoogle Scholar
• 66 Fleming CA, Heneghan HM, OʼBrien D. et al. Meta-analysis of the cumulative risk of endometrial malignancy and systematic review of endometrial surveillance in extended tamoxifen therapy. Br J Surg 2018; 105: 1098-1106
  CrossrefPubMedGoogle Scholar
• 67 Saccardi C, Gizzo S, Patrelli TS. et al. Endometrial surveillance in tamoxifen users: role, timing and accuracy of hysteroscopic investigation: observational longitudinal cohort study. Endocr Relat Cancer 2013; 20: 455-462
  CrossrefPubMedGoogle Scholar
• 68 Gao WL, Zhang LP, Feng LM. Comparative study of transvaginal ultrasonographic and diagnostic hysteroscopic findings in postmenopausal breast cancer patients treated with tamoxifen. Chin Med J (Engl) 2011; 124: 2335-2339
  PubMedGoogle Scholar
• 69 Bertelli G, Valenzano M, Costantini S. et al. Limited value of sonohysterography for endometrial screening in asymptomatic, postmenopausal patients treated with tamoxifen. Gynecol Oncol 2000; 78: 275-277
  CrossrefPubMedGoogle Scholar
• 70 Gerber B, Krause A, Muller H. et al. Effects of adjuvant tamoxifen on the endometrium in postmenopausal women with breast cancer: a prospective long-term study using transvaginal ultrasound. J Clin Oncol 2000; 18: 3464-3470
  CrossrefPubMedGoogle Scholar
• 71 Fung MF, Reid A, Faught W. et al. Prospective longitudinal study of ultrasound screening for endometrial abnormalities in women with breast cancer receiving tamoxifen. Gynecol Oncol 2003; 91: 154-159
  CrossrefPubMedGoogle Scholar
• 72 Pennant ME, Mehta R, Moody P. et al. Premenopausal abnormal uterine bleeding and risk of endometrial cancer. BJOG 2016; 124: 404-411
  CrossrefPubMedGoogle Scholar
• 73 Huang GS, Gebb JS, Einstein MH. et al. Accuracy of preoperative endometrial sampling for the detection of high-grade endometrial tumors. Am J Obstet Gynecol 2007; 196: 243.e1-243.e5
  CrossrefPubMedGoogle Scholar
• 74 Leitao jr. MM, Kehoe S, Barakat RR. et al. Accuracy of preoperative endometrial sampling diagnosis of FIGO grade 1 endometrial adenocarcinoma. Gynecol Oncol 2008; 111: 244-248
  CrossrefPubMedGoogle Scholar
• 75 Clark TJ, Mann CH, Shah N. et al. Accuracy of outpatient endometrial biopsy in the diagnosis of endometrial cancer: a systematic quantitative review (Structured abstract). BJOG 2002; 109: 313-321
  CrossrefPubMedGoogle Scholar
• 76 Al-Azemi M, Labib NS, Motawy MM. et al. Prevalence of endometrial proliferation in pipelle biopsies in tamoxifen-treated postmenopausal women with breast cancer in Kuwait. Med Princ Pract 2003; 13: 30-34
  CrossrefPubMedGoogle Scholar
• 77 Timmermans A, Opmeer BC, Khan KS. et al. Endometrial thickness measurement for detecting endometrial cancer in women with postmenopausal bleeding: a systematic review and meta-analysis. Obstet Gynecol 2010; 116: 160-167
  CrossrefPubMedGoogle Scholar
• 78 Savelli L, Ceccarini M, Ludovisi M. et al. Preoperative local staging of endometrial cancer: transvaginal sonography vs. magnetic resonance imaging. Ultrasound Obstet Gynecol 2008; 31: 560-566
  CrossrefPubMedGoogle Scholar
• 79 Endometriumcarcinoom. 2011. Accessed July 25, 2023 at: https://www.oncoline.nl/endometriumcarcinoom
  PubMedGoogle Scholar
• 80 Lalwani N, Dubinsky T, Javitt MC. et al. ACR Appropriateness Criteria(^®) pretreatment evaluation and follow-up of endometrial cancer. Ultrasound Q 2014; 30: 21-28
  CrossrefPubMedGoogle Scholar
• 81 Selman TJ, Mann CH, Zamora J. et al. A systematic review of tests for lymph node status in primary endometrial cancer. BMC Womens Health 2008; 8: 8
  CrossrefPubMedGoogle Scholar
• 82 Chang MC, Chen JH, Liang JA. et al. 18F-FDG PET or PET/CT for detection of metastatic lymph nodes in patients with endometrial cancer: a systematic review and meta-analysis. Eur J Radiol 2012; 81: 3511-3517
  CrossrefPubMedGoogle Scholar
• 83 Kakhki VR, Shahriari S, Treglia G. et al. Diagnostic performance of fluorine 18 fluorodeoxyglucose positron emission tomography imaging for detection of primary lesion and staging of endometrial cancer patients: systematic review and meta-analysis of the literature. Int J Gynecol Cancer 2013; 23: 1536-1543
  CrossrefPubMedGoogle Scholar
• 84 Antonsen SL, Jensen LN, Loft A. et al. MRI, PET/CT and ultrasound in the preoperative staging of endometrial cancer – a multicenter prospective comparative study. Gynecol Oncol 2012; 128: 300-308
  CrossrefPubMedGoogle Scholar
• 85 León-Castillo A, de Boer SM, Powell ME. et al. Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy. J Clin Oncol 2020; 38: 3388-3397
  PubMedGoogle Scholar
• 86 Stelloo E, Nout RA, Osse EM. et al. Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer-Combined Analysis of the PORTEC Cohorts. Clin Cancer Res 2016; 22: 4215-4224
  CrossrefPubMedGoogle Scholar
• 87 Wortman BG, Creutzberg CL, Putter H. et al. Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy. Br J Cancer 2018; 119: 1067-1074
  CrossrefPubMedGoogle Scholar
• 88 Reijnen C, Küsters-Vandevelde HVN, Prinsen CF. et al. Mismatch repair deficiency as a predictive marker for response to adjuvant radiotherapy in endometrial cancer. Gynecol Oncol 2019; 154: 124-130
  CrossrefPubMedGoogle Scholar
• 89 Bosse T, Peters EE, Creutzberg CL. et al. Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer–A pooled analysis of PORTEC1 and 2 trials. Eur J Cancer 2015; 51: 1742-1750
  CrossrefPubMedGoogle Scholar
• 90 Kandoth C, McLellan MD, Vandin F. et al. Mutational landscape and significance across 12 major cancer types. Nature 2013; 502: 333-339
  CrossrefPubMedGoogle Scholar
• 91 Coll-de la Rubia E, Martinez-Garcia E, Dittmar G. et al. Prognostic Biomarkers in Endometrial Cancer: A Systematic Review and Meta-Analysis. J Clin Med 2020; 9: 1900
  CrossrefPubMedGoogle Scholar
• 92 León-Castillo A, de Boer SM, Powell ME. et al. Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy. J Clin Oncol 2020; 38: 3388-3397
  CrossrefPubMedGoogle Scholar
• 93 Wortman BG, Creutzberg CL, Putter H. et al. Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy. Br J Cancer 2018; 119: 1067-1074
  CrossrefPubMedGoogle Scholar
• 94 Bosse T, Nout RA, McAlpine JN. et al. Molecular Classification of Grade 3 Endometrioid Endometrial Cancers Identifies Distinct Prognostic Subgroups. Am J Surg Pathol 2018; 42: 561-568
  CrossrefPubMedGoogle Scholar
• 95 Kommoss S, McConechy MK, Kommoss F. et al. Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series. Ann Oncol 2018; 29: 1180-1188
  CrossrefPubMedGoogle Scholar
• 96 Kandoth C, Schultz N, Cherniack AD. et al. Integrated genomic characterization of endometrial carcinoma. Nature 2013; 497: 67-73
  CrossrefPubMedGoogle Scholar
• 97 Wortman BG, Bosse T, Nout RA. et al. Molecular-integrated risk profile to determine adjuvant radiotherapy in endometrial cancer: Evaluation of the pilot phase of the PORTEC-4a trial. Gynecol Oncol 2018; 151: 69-75
  CrossrefPubMedGoogle Scholar
• 98 Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 1983; 15: 10-17
  CrossrefPubMedGoogle Scholar
• 99 Lax SF, Kurman RJ. A dualistic model for endometrial carcinogenesis based on immunohistochemical and molecular genetic analyses. Verh Dtsch Ges Pathol 1997; 81: 228-232
  PubMedGoogle Scholar
• 100 Lax SF, Kurman RJ, Pizer ES. et al. A binary architectural grading system for uterine endometrial endometrioid carcinoma has superior reproducibility compared with FIGO grading and identifies subsets of advance-stage tumors with favorable and unfavorable prognosis. Am J Surg Pathol 2000; 24: 1201-1208
  CrossrefPubMedGoogle Scholar
• 101 Lax SF. Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification. Virchows Arch 2004; 444: 213-223
  CrossrefPubMedGoogle Scholar
• 102 Wittekind C, Meyer HJ. TNM Klassifikation maligner Tumoren. Weinheim: Wiley-VCH; 2010
  Google Scholar
• 103 de Jonge MM, Ritterhouse LL, de Kroon CD. et al. HEBON Group. Germline BRCA-Associated Endometrial Carcinoma Is a Distinct Clinicopathologic Entity. Clin Cancer Res 2019; 25: 7517-7526
  CrossrefPubMedGoogle Scholar
• 104 Van Gool IC, Ubachs JEH, Stelloo E. et al. Blinded histopathological characterisation of POLE exonuclease domain-mutant endometrial cancers: sheep in wolfʼs clothing. Histopathology 2018; 72: 248-258
  CrossrefPubMedGoogle Scholar
• 105 Vermij L, Smit V, Nout R. et al. Incorporation of molecular characteristics into endometrial cancer management. Histopathology 2020; 76: 52-63
  CrossrefPubMedGoogle Scholar
• 106 Casey L, Singh N. POLE, MMR, and MSI Testing in Endometrial Cancer: Proceedings of the ISGyP Companion Society Session at the USCAP 2020 Annual Meeting. Int J Gynecol Pathol 2021; 40: 5-16
  CrossrefPubMedGoogle Scholar
• 107 Talhouk A, Hoang LN, McConechy MK. et al. Molecular classification of endometrial carcinoma on diagnostic specimens is highly concordant with final hysterectomy: Earlier prognostic information to guide treatment. Gynecol Oncol 2016; 143: 46-53
  CrossrefPubMedGoogle Scholar
• 108 Lax SF. Pathology of Endometrial Carcinoma. In: Hedrick Ellenson L, ed. Molecular Genetics of Endometrial Carcinoma. Cham: Springer International Publishing;; 2017: 75-96
  CrossrefGoogle Scholar
• 109 Talhouk A, McConechy MK, Leung S. et al. A clinically applicable molecular-based classification for endometrial cancers. Br J Cancer 2015; 113: 299-310
  CrossrefPubMedGoogle Scholar
• 110 Jönsson JM, Bååth M, Björnheden I. et al. Homologous Recombination Repair Mechanisms in Serous Endometrial Cancer. Cancers (Basel) 2021; 13: 254
  CrossrefPubMedGoogle Scholar
• 111 Concin N, Matias-Guiu X, Vergote I. et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Int J Gynecol Cancer 2021; 31: 12-39
  CrossrefPubMedGoogle Scholar
• 112 ten Broeke SW, Brohet RM, Tops CM. et al. Lynch syndrome caused by germline PMS2 mutations: delineating the cancer risk. J Clin Oncol 2014; 33: 319-325
  CrossrefPubMedGoogle Scholar
• 113 Buchanan DD, Tan YY, Walsh MD. et al. Tumor mismatch repair immunohistochemistry and DNA MLH1 methylation testing of patients with endometrial cancer diagnosed at age younger than 60 years optimizes triage for population-level germline mismatch repair gene mutation testing. J Clin Oncol 2013; 32: 90-100
  CrossrefPubMedGoogle Scholar
• 114 Carcangiu ML, Radice P, Casalini P. et al. Lynch syndrome–related endometrial carcinomas show a high frequency of nonendometrioid types and of high FIGO grade endometrioid types. Int J Surg Pathol 2009; 18: 21-26
  CrossrefPubMedGoogle Scholar
• 115 Dowty JG, Win AK, Buchanan DD. et al. Cancer risks for MLH1 and MSH2 mutation carriers. Hum Mutat 2012; 34: 490-497
  CrossrefPubMedGoogle Scholar
• 116 Egoavil C, Alenda C, Castillejo A. et al. Prevalence of Lynch syndrome among patients with newly diagnosed endometrial cancers. PLoS One 2013; 8: e79737
  CrossrefPubMedGoogle Scholar
• 117 Hampel H, Frankel W, Panescu J. et al. Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients. Cancer Res 2006; 66: 7810-7817
  PubMedGoogle Scholar
• 118 Leenen CH, van Lier MG, van Doorn HC. et al. Prospective evaluation of molecular screening for Lynch syndrome in patients with endometrial cancer </= 70 years. Gynecol Oncol 2012; 125: 414-420
  PubMedGoogle Scholar
• 119 Lu KH, Schorge JO, Rodabaugh KJ. et al. Prospective determination of prevalence of lynch syndrome in young women with endometrial cancer. J Clin Oncol 2007; 25: 5158-5164
  CrossrefPubMedGoogle Scholar
• 120 Westin SN, Lacour RA, Urbauer DL. et al. Carcinoma of the lower uterine segment: a newly described association with Lynch syndrome. J Clin Oncol 2008; 26: 5965-5971
  CrossrefPubMedGoogle Scholar
• 121 Win AK, Lindor NM, Winship I. et al. Risks of colorectal and other cancers after endometrial cancer for women with Lynch syndrome. J Natl Cancer Inst 2013; 105: 274-279
  CrossrefPubMedGoogle Scholar
• 122 Hampel H, de la Chapelle A. The search for unaffected individuals with Lynch syndrome: do the ends justify the means?. Cancer Prev Res (Phila) 2011; 4: 1-5
  CrossrefPubMedGoogle Scholar
• 123 Win AK, Jenkins MA, Dowty JG. et al. Prevalence and Penetrance of Major Genes and Polygenes for Colorectal Cancer. Cancer Epidemiol Biomarkers Prev 2017; 26: 404-412
  CrossrefPubMedGoogle Scholar
• 124 Nelen MR, Kremer H, Konings IB. et al. Novel PTEN mutations in patients with Cowden disease: absence of clear genotype-phenotype correlations. Eur J Hum Genet 1999; 7: 267-273
  CrossrefPubMedGoogle Scholar
• 125 Ryan NAJ, Glaire MA, Blake D. et al. The proportion of endometrial cancers associated with Lynch syndrome: a systematic review of the literature and meta-analysis. Genet Med 2019; 21: 2167-2180
  CrossrefPubMedGoogle Scholar
• 126 Snowsill TM, Ryan NAJ, Crosbie EJ. et al. Cost-effectiveness analysis of reflex testing for Lynch syndrome in women with endometrial cancer in the UK setting. PLoS One 2019; 14: e0221419
  CrossrefPubMedGoogle Scholar
• 127 Dominguez-Valentin M, Sampson JR, Seppälä TT. et al. Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database. Genet Med 2020; 22: 15-25
  CrossrefPubMedGoogle Scholar
• 128 Riegert-Johnson DL, Gleeson FC, Roberts M. et al. Cancer and Lhermitte-Duclos disease are common in Cowden syndrome patients. Hered Cancer Clin Pract 2010; 8: 6
  CrossrefPubMedGoogle Scholar
• 129 Tan MH, Mester JL, Ngeow J. et al. Lifetime cancer risks in individuals with germline PTEN mutations. Clin Cancer Res 2012; 18: 400-407
  CrossrefPubMedGoogle Scholar
• 130 Hampel H, Frankel W, Panescu J. et al. Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients. Cancer Res 2006; 66: 7810-7817
  CrossrefPubMedGoogle Scholar
• 131 Ferguson SE, Aronson M, Pollett A. et al. Performance characteristics of screening strategies for Lynch syndrome in unselected women with newly diagnosed endometrial cancer who have undergone universal germline mutation testing. Cancer 2014; 120: 3932-3939
  CrossrefPubMedGoogle Scholar
• 132 Leenen CH, van Lier MG, van Doorn HC. et al. Prospective evaluation of molecular screening for Lynch syndrome in patients with endometrial cancer = 70 years. Gynecol Oncol 2012; 125: 414-420
  CrossrefPubMedGoogle Scholar
• 133 Bubien V, Bonnet F, Brouste V. et al. High cumulative risks of cancer in patients with PTEN hamartoma tumour syndrome. J Med Genet 2013; 50: 255-263
  CrossrefPubMedGoogle Scholar
• 134 Clarke BA, Cooper K. Identifying Lynch syndrome in patients with endometrial carcinoma: shortcomings of morphologic and clinical schemas. Adv Anat Pathol 2012; 19: 231-238
  CrossrefPubMedGoogle Scholar
• 135 Snowsill T, Huxley N, Hoyle M. et al. A systematic review and economic evaluation of diagnostic strategies for Lynch syndrome. Health Technol Assess 2014; 18: 1-406
  CrossrefPubMedGoogle Scholar
• 136 Auranen A, Joutsiniemi T. A systematic review of gynecological cancer surveillance in women belonging to hereditary nonpolyposis colorectal cancer (Lynch syndrome) families. Acta Obstet Gynecol Scand 2011; 90: 437-444
  CrossrefPubMedGoogle Scholar
• 137 Lecuru F, Le Frere Belda MA, Bats AS. et al. Performance of office hysteroscopy and endometrial biopsy for detecting endometrial disease in women at risk of human non-polyposis colon cancer: a prospective study. Int J Gynecol Cancer 2008; 18: 1326-1331
  CrossrefPubMedGoogle Scholar
• 138 Mohile SG, Dale W, Somerfield MR. et al. Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Chemotherapy: ASCO Guideline for Geriatric Oncology. J Clin Oncol 2018; 36: 2326-2347
  CrossrefPubMedGoogle Scholar
• 139 Decoster L, Van Puyvelde K, Mohile S. et al. Screening tools for multidimensional health problems warranting a geriatric assessment in older cancer patients: an update on SIOG recommendations†. Ann Oncol 2015; 26: 288-300
  CrossrefPubMedGoogle Scholar
• 140 Nadaraja S, Jørgensen TL, Matzen LE. et al. Impact of Age, Comorbidity, and FIGO Stage on Treatment Choice and Mortality in Older Danish Patients with Gynecological Cancer: A Retrospective Register-Based Cohort Study. Drugs Real World Outcomes 2018; 5: 225-235
  CrossrefPubMedGoogle Scholar
• 141 Bourgin C, Saidani M, Poupon C. et al. Endometrial cancer in elderly women: Which disease, which surgical management? A systematic review of the literature. Eur J Surg Oncol 2016; 42: 166-175
  CrossrefPubMedGoogle Scholar
• 142 Driver JA, Viswanathan AN. Frailty measure is more predictive of outcomes after curative therapy for endometrial cancer than traditional risk factors in women 60 and older. Gynecol Oncol 2017; 145: 526-530
  CrossrefPubMedGoogle Scholar
• 143 Ahmed A, Deng W, Tew W. et al. Pre-operative assessment and post-operative outcomes of elderly women with gynecologic cancers, primary analysis of NRG CC-002: An NRG oncology group/gynecologic oncology group study. Gynecol Oncol 2018; 150: 300-305
  CrossrefPubMedGoogle Scholar
• 144 Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF). S3-Leitlinie Mammakarzinom, Langversion 4.3, AWMF-Registernummer: 032–045OL. 2020. Accessed July 22, 2023 at: https://www.leitlinienprogramm-onkologie.de/leitlinien/mammakarzinom/
  PubMedGoogle Scholar
• 145 Bauer J, Denkinger M, Freiberger E. et al. S1-Leitlinie „Geriatrisches Assessment der Stufe 2. 2019. Accessed June 02, 2023 at: https://www.awmf.org/leitlinien/detail/ll/084-002.html
  PubMedGoogle Scholar